Sarcoidosis is a multi-systemic disease of unknown etiology with a clinical presentation ranging from asymptomatic disease to ...

A 36-year-old man with a 6-month history of asthenia, impotence, loss of libido, polyuria, and polydipsia attended our department; he also reported needing to wake up twice at night to urinate and ...

Sarcoidosis is a rare inflammatory condition that develops when groups of cells in your immune system form patches of swollen ...

Sarcoidosis patients have a disease burden that is physical, emotional, and usually complicated by psychosocial problems because it affects people during the most productive years of their lives.

Boston)—Sarcoidosis is a multi-systemic disease of unknown etiology with a clinical presentation ranging from asymptomatic disease to organ failure ...

Sarcoidosis is a systemic disease of unknown etiology. It is characterized by the presence of non-necrotizing granulomas distributed along the lymphatics in the peribronchovascular (axial ...

Namilumab failed to show treatment benefit in patients with pulmonary sarcoidosisFurther development of namilumab for the treatment of ...

SAN DIEGO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company ...

Kinevant Sciences, a Roivant spinout designed to test an investigational monoclonal antibody, has reported that the asset ...

The global burden of ILD and pulmonary sarcoidosis increased by 169% from 1990 to 2021, with high-SDI countries most affected. ILDs, including idiopathic pulmonary fibrosis, have a poor prognosis ...

Roivant Sciences said its subsidiary Kinevant Sciences' phase 2 study of Namilumab failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis.

Sarcoidosis is a multi-systemic disease of unknown etiology with a clinical presentation ranging from asymptomatic disease to organ failure. While some patients with sarcoidosis have spontaneous ...